Hepatolenticular degeneration animal model, construction method and application
The ATP7B gene defect model was constructed in C57BL/6J mice through CRISPR/Cas9 technology, which solved the shortcomings of the genetic background and construction methods in the existing technology, achieved efficient and accurate gene editing, and provided a reliable liver bean-like nucleus Degenerative animal model for research and new drug development.
Patent Information
- Application Number
- CN202411365193.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-12-03
AI Technical Summary
The existing animal models of hepato-like nuclear degeneration have low diversity, phenotypic instability and high technical complexity in terms of genetic background and construction methods, which limit the universality and efficiency of the experiment.
The ATP7B gene defect model was constructed in C57BL/6J mice using CRISPR/Cas9 technology, mutations were introduced through non-homologous recombination repair, and the Atp7b gene knockdown was designed to achieve efficient and accurate gene editing.
Gene knockout mouse models with clear genetic background were generated, which improved gene editing efficiency and accuracy, reduced resources and costs, and provided a reliable research material to understand the pathogenesis of hepatoli nuclear degeneration and assisted in the development of new drugs.
Smart Images

Figure CN119061069A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of animal model construction, in particular to an invention name. Background Art
[0002] Hepatolenticular degeneration (HLD), also known as Wilson's disease, is an autosomal recessive copper metabolism disorder. The main pathogenic mechanism is that the mutation of the ATPaseCu2+transporting beta polypeptide (ATP7B) gene leads to weakened or lost ATPase function. The resulting copper metabolism disorder can lead to lesions in multiple organs such as the liver and nervous system. HD has an insidious and non-specific onset and can cause disability or even death if not treated in time. Although the environment and epigenetics are widely involved in the occurrence and development of HLD, toxic copper accumulation caused by Atp7b gene mutation is still considered to be the main cause of HLD pathological damage. Therefore, a stable copper metabolism disorder model is helpful to understand the role of copper toxicity in the pathogenesis of HLD and is conducive to the development of new HLD drugs.
[0003] HLD model species include mice, rats, rabbits and dogs. Among them, the experimental costs of rats, rabbits and dogs are high, and the evaluation of the models takes a long time, so they have not been widely used in basic research. The most widely used one is the Atp7b gene mutant mouse model generated by ES targeting technology, which was reported in 1999. This model was artificially constructed by inserting the PGK-neo gene cassette encoding multiple terminators into the exon 2 region of the Atp7b gene of wild-type mice (C57BL and 129S6 / SvEv hybrid strains). Similar to the symptoms of HLD patients, mutant mice show copper ion accumulation in liver, kidney and brain tissues, with significant liver histological damage and certain nervous system abnormalities. In addition to gene editing models, toxic milk mice (tx-j mice) from the C3H / HeJ strain, which are generated by spontaneous Atp7b gene mutations, are also often used to study diseases related to copper metabolism.
[0004] Although the existing HLD animal models can be used as experimental materials for the study of HLD pathophysiology, copper metabolism, inflammation and defense mechanisms, there are certain shortcomings in the genetic background and construction methods of the models:
[0005] In terms of genetic background, the genetic diversity of the inbred HLD mouse model of spontaneous disease is low, which limits the generalizability of the experimental results. Different genetic backgrounds may affect the phenotype of gene mutations, so a single inbred strain of mice may not fully reflect all phenotypes observed in humans.
[0006] From the construction method, spontaneous mutations occur randomly, and researchers cannot control the location and type of mutations, which may cause some mutations to have no research value or bring unexpected phenotypic effects. At the same time, since spontaneous mutant mice are produced through inbreeding, their phenotypes may vary in different inbreeding generations. This phenotypic instability will affect the reliability of the experimental results. In addition, the ES targeting technology for constructing gene-edited animal models has the disadvantages of high technical complexity and low efficiency. Due to the low efficiency of homologous recombination in ES cells, a large number of cells need to be screened to obtain successful gene-targeted cells. This increases the time and resource consumption of the experiment.
[0007] CRISPR / Cas9 technology is currently the most intensively studied and most maturely applied efficient gene editing tool. It consists of a Cas protein with endonuclease function and a single-stranded guide RNA (sgRNA) of an artificially recombined target gene. The sgRNA can guide the Cas protein to knock out, insert, and mutate the target gene. Compared with traditional gene targeting technology, CRISPR / Cas9 technology is simple to operate, low in cost, and does not require complex homologous recombination steps. At present, there is no animal model based on CRISPR / Cas9 technology for the study of HLD treatment methods. Summary of the invention
[0008] In view of the above-mentioned defects of the prior art, the present invention constructs an ATP7B gene-deficient mouse model in mice of a single genetic background (C57BL / 6J) by using CRISPR / Cas9 technology with higher editing efficiency, providing reliable research materials for the pathogenesis of hepatolenticular degeneration and the development of new drugs.
[0009] To achieve the above object, the present invention provides an animal model of hepatolenticular degeneration, in which the Atp7b gene is not expressed or its expression is inhibited, so that the animal model exhibits characteristics of hepatolenticular degeneration. The animal model can be used as a hepatolenticular degeneration disease model for the study of copper metabolism disorders, and can also help clarify the disease mechanism of asymptomatic hepatolenticular degeneration, enrich the theoretical basis of hepatolenticular degeneration, and assist in the development of treatment methods for hepatolenticular degeneration.
[0010] On the other hand, the present invention provides a method for constructing an animal model of hepatolenticular degeneration, which uses non-homologous recombination repair to introduce mutations, causing frame shift and functional loss of the Atp7b gene protein in the animal model. The present invention designs guide RNA for the intron 1 and intron 3 sequences of the Atp7b gene, and achieves knockout of the Atp7b gene by specifically removing the entire exon 2 region.
[0011] The present invention also provides a method for constructing an animal model of hepatolenticular degeneration, the method comprising the following steps:
[0012] (1) Obtain Cas9 mRNA and two gRNAs by in vitro transcription;
[0013] (2) Microinjection of Cas9 mRNA and gRNA into fertilized eggs of C57BL / 6J mice;
[0014] (3) The injected fertilized eggs are transplanted into pseudo-pregnant female mice, and the mice born are F0 generation mice;
[0015] (4) genotyping by PCR amplification and sequencing;
[0016] (5) F0 mice that were positive for PCR amplification and sequencing were mated with C57BL / 6J mice to obtain positive F1 mice;
[0017] (6) The F1 generation mice with stable inheritance continued to mate and reproduce to obtain homozygous mutant Atp7b-deficient mice.
[0018] The present invention provides an animal model of Wilson's disease, characterized in that the animal model is constructed by the above-mentioned construction method.
[0019] The present invention also provides a use of the above animal model as a mechanism for the pathogenesis of hepatolenticular degeneration or for the development of new drugs.
[0020] Preferably, the animal model is used as a Wilson's disease model for the study of copper metabolism disorders.
[0021] Preferably, the animal model is used to clarify the disease mechanism of asymptomatic Wilson's disease, enrich the theoretical basis of Wilson's disease, and assist in the development of treatments for Wilson's disease.
[0022] Beneficial technical effects of the present invention:
[0023] (1) The mouse model constructed in the present invention is from the C57BL / 6J background. Compared with the existing inbred strains, this gene knockout mouse model has a clear genetic background, which is convenient for comparison with the original control strain.
[0024] (2) Compared with the complex ES targeting technology, CRISPR / Cas9 technology has a higher gene editing efficiency and can generate a large number of gene knockout mice in a short period of time. By designing specific guide RNA, CRISPR / Cas9 can accurately target specific sequences in the genome for editing, thereby reducing off-target effects and improving the accuracy of gene editing.
[0025] (3) Compared with the traditional mouse model of HLD, the operation of the present invention is simple and efficient, and the required resources and costs are relatively low.
[0026] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a strategy diagram for constructing ATP7B knockout mice based on CRISPR / Cas9 technology;
[0028] Figure 2 This is the electrophoresis diagram of gene detection and identification of ATP7B gene knockout mice;
[0029] Among them: WT is wild-type mouse, HE is heterozygous Atp7b- / - mouse, and KO is homozygous Atp7b- / - mouse.
[0030] Figure 3 This is the electrophoresis diagram based on the detection and identification of the exon 2 region of Atp7b gene knockout mice based on cDNA;
[0031] Figure 4 is the real-time quantitative PCR to detect the expression of Atp7b gene in mouse liver;
[0032] Figure 5 It is the result of inductively coupled plasma mass spectrometry detection of copper content in mouse liver;
[0033] in: Figure 5 A is the liver copper level of wild-type / heterozygous / homozygous Atp7b knockout mice at 20 weeks of age. Figure 5 B shows the liver copper level of homozygous Atp7b knockout mice at different ages (it can be seen that the liver copper level of homozygous Atp7b knockout mice increased by about 100 times compared with wild-type mice at 5 weeks of age).
[0034] Figure 6 It is the result of inductively coupled plasma mass spectrometry detection of copper content in mouse brain tissue;
[0035] in: Figure 6 A is the copper content in the striatum of wild-type / homozygous Atp7b knockout mice, Figure 6 B is the copper content in the hippocampus of wild-type / homozygous Atp7b knockout mice.
[0036] Figure 7 The 24-hour urinary copper excretion of mice was detected by inductively coupled plasma mass spectrometry;
[0037] Figure 8The 24-hour urinary copper excretion of wild-type / homozygous Atp7b knockout mice was detected under the copper overload experiment;
[0038] Fig. 9 The total copper content in mouse plasma was detected by inductively coupled plasma mass spectrometry;
[0039] Fig.10 This is the result of the plasma ceruloplasmin activity test in Atp7b gene knockout mice;
[0040] Fig.11 Western blotting was used to detect the expression level of plasma ceruloplasmin in Atp7b gene knockout mice. DETAILED DESCRIPTION
[0041] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.
[0042] The present invention provides an animal model of hepatolenticular degeneration, in which the Atp7b gene is not expressed or its expression is inhibited, so that the animal model exhibits characteristics of hepatolenticular degeneration. The animal model can be used as a hepatolenticular degeneration disease model for the study of copper metabolism disorders, and can also help clarify the disease mechanism of asymptomatic hepatolenticular degeneration, enrich the theoretical basis of hepatolenticular degeneration, and assist in the research and development of treatment methods for hepatolenticular degeneration.
[0043] The present invention utilizes non-homologous recombination repair to introduce mutations, causing frame shift and functional loss of the Atp7b gene protein in an animal model. The present invention designs guide RNA for the intron 1 and intron 3 sequences of the Atp7b gene, and achieves knockout of the Atp7b gene by specifically removing the entire exon 2 region.
[0044] The present invention also provides a method for constructing an animal model of hepatolenticular degeneration, the method comprising the following steps:
[0045] (1) Obtain Cas9 mRNA and two gRNAs by in vitro transcription;
[0046] (2) Microinjection of Cas9 mRNA and gRNA into fertilized eggs of C57BL / 6J mice;
[0047] (3) The injected fertilized eggs are transplanted into pseudo-pregnant female mice, and the mice born are F0 generation mice;
[0048] (4) genotyping by PCR amplification and sequencing;
[0049] (5) F0 mice that were positive for PCR amplification and sequencing were mated with C57BL / 6J mice to obtain positive F1 mice;
[0050] (6) The F1 generation mice with stable inheritance continued to mate and reproduce to obtain homozygous mutant Atp7b-deficient mice.
[0051] The present invention provides a method of using the above animal model as a hepatolenticular degeneration pathogenesis or new drug development, as a hepatolenticular degeneration disease model, for the study of copper metabolism disorders. It is also used to clarify the disease mechanism of asymptomatic hepatolenticular degeneration, enrich the theoretical basis of hepatolenticular degeneration, and assist in the development of treatment methods for hepatolenticular degeneration.
[0052] The mouse model constructed by the present invention is from the C57BL / 6J background. Compared with the existing inbred strains, this gene knockout mouse model has a clear genetic background, which is convenient for comparison with the original control strain. Compared with the complex ES targeting technology, CRISPR / Cas9 technology has a higher gene editing efficiency and can generate a large number of gene knockout mice in a short time. By designing specific guide RNA, CRISPR / Cas9 can accurately target specific sequences in the genome for editing, thereby reducing off-target effects and improving the accuracy of gene editing. Compared with the traditional HLD mouse model, the operation of the present invention is simple and efficient, and the required resources and costs are relatively low.
[0053] like Figure 1 As shown, the C57BL / 6J mice involved in the present invention are obtained from Shanghai Model Organisms Science Co., Ltd. The two sgRNA sequences targeting the mouse Atp7b gene are as follows:
[0054]
[0055] The technical solution of the present invention is further described below in conjunction with specific embodiments.
[0056] Example 1 Genotype Identification
[0057] Based on genomic DNA, the PCR results of wild-type or heterozygous / homozygous Atp7b knockout mouse genotype identification corresponded to the amplification product size of 2565bp for wild-type and 723bp for mutant. A single 2565bp band appeared for wild-type mice, a single 723bp band appeared for homozygous Atp7b knockout mice, and if both 2565bp and 723bp bands appeared at the same time, it indicated that the mouse was a heterozygous Atp7b knockout mouse.
[0058] The specific primers used for PCR identification are as follows:
[0059]
[0060] Used to amplify a fragment of 2565 bp;
[0061]
[0062] Used to amplify a fragment of 723 bp.
[0063] The gene sequence was amplified by conventional PCR using specific primers based on cDNA, and the presence or absence of exon 2 region of mouse Atp7b gene was verified for a second time.
[0064] The size of the PCR amplification product is 2002bp for the wild type and 795bp for the mutant type. A single 2002bp band appears in wild-type mice, a single 795bp band appears in homozygous Atp7b knockout mice, and if both 2002bp and 795bp bands appear at the same time, it indicates that the mouse is a heterozygous Atp7b knockout mouse.
[0065] The identification primer sequences used are as follows:
[0066]
[0067] Results reference Figure 2 and Figure 3 , only a single truncated band appeared in homozygous Atp7b knockout mice, indicating that the target region had been successfully knocked out.
[0068] Example 2 RT-PCR detection of Atp7b gene expression in mouse liver
[0069] According to the kit instructions, use Total RNA from mouse liver tissue was extracted using Super Total RNA Extraction Kit (Promega, Shanghai), and then reverse transcribed using HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, Nanjing) to produce cDNA.
[0070] Real-time PCR reaction was performed using cDNA, with GAPDH as internal reference and primers as follows:
[0071]
[0072] The primer sequences used to amplify the Atp7b gene are:
[0073]
[0074] The PCR reaction conditions were as follows: pre-denaturation at 95°C for 30 s, 95°C for 10 s, and 60°C for 30 s, for 40 cycles.
[0075] Results reference Figure 4 As shown, there is no transcriptional expression of Atp7b gene in homozygous Atp7b knockout mice.
[0076] Example 3 Detection of copper content in various tissues of mice
[0077] The day before sacrifice, the urine and feces of mice were collected within 24 hours using metabolic cages. After the mice were sacrificed, whole blood was collected and plasma was obtained by centrifugation at 3000rpm for 15 minutes. A piece of liver tissue (about 100-200mg) was collected from the right lobe of the liver for detection. The hippocampus and striatum of the brain regions were separated and prepared into tissue homogenate using RIPA lysis buffer. The samples were weighed before detection, and 100-200mg of the sample was mixed with 4ml of acid solution (1ml of nitric acid and 3ml of hydrochloric acid). The mixture was heated at 120°C on a graphite furnace for 1 hour. The digested sample was diluted to 10ml with ultrapure water and then filtered using a 0.22μm filter membrane. Subsequent inductively coupled plasma mass spectrometry detection was completed by Shanghai Micro Spectrum Detection Technology Co., Ltd.
[0078] Results reference Figures 5 to 7 and Fig. 9 Homozygous Atp7b knockout mice showed a phenotype with significantly increased liver copper, brain copper, and urine copper levels, and significantly decreased blood copper levels. These characteristics are typical characteristics of Wilson's disease. This fully demonstrates that using CRISPR / Cas9 technology to knock out the Atp7b gene can cause copper metabolism disorders in target animals.
[0079] Example 4 Copper overload experiment
[0080] Ten wild-type and homozygous Atp7b knockout mice were randomly divided into four groups, namely, wild-type control group, wild-type copper overload group, homozygous control group, and homozygous copper overload group. The wild-type copper overload group and the homozygous copper overload group were intraperitoneally injected with 100 μg of copper sulfate solution, and the wild-type control group and the homozygous control group were intraperitoneally injected with the same volume of sterile ultrapure water. After injection, the mice were placed in metabolic cages (one per cage) and fasted but not watered. All urine and feces of the mice were collected within 24 hours. The copper ion content in the excreta was then detected using inductively coupled plasma mass spectrometry.
[0081] Results reference Figure 8 In the control group that did not receive copper sulfate injection, the urinary copper content of homozygous mice was significantly higher than that of wild-type mice at baseline. Under the condition of copper overload, the urinary copper content of homozygous mice increased significantly, while the increase in urinary copper of wild-type mice was limited. This shows that the copper excretion capacity of Atp7b gene knockout mice is reduced and the copper metabolism capacity is significantly impaired.
[0082] Example 5 Detection of Plasma Ceruloplasmin Activity
[0083] According to the kit instructions, the activity of mouse plasma ceruloplasmin was detected by colorimetry using the ceruloplasmin (CP) assay kit (Nanjing, Nanjing). The specific implementation steps are as follows: 20 μl of plasma, 320 μl of buffer, and 80 μl of matrix solution were added to the sample tube, and only 320 μl and 80 μl of buffer and matrix solution were added to the control tube, mixed, and placed in a 37°C water bath for 20 minutes. Subsequently, 800 μl of terminator was added to the sample tube, and 800 μl of terminator and 20 μl of ddH2O were added to the control tube, mixed, and placed at room temperature for 5 minutes. 200 μl of the mixed solution was aspirated and placed in a 96-well plate, and the absorbance was measured at 540 nm using a multifunctional microplate reader. The ceruloplasmin activity was calculated according to the calculation method provided by the kit.
[0084] Results reference Fig.10 Atp7b gene knockout resulted in a significant decrease in the catalytic activity of mouse ceruloplasmin, indicating that the function of ATP7B protein was impaired, verifying the efficiency of gene knockout.
[0085] Example 6 Protein immunoblotting to detect the expression of ceruloplasmin
[0086] Blood samples from wild-type and homozygous Atp7b knockout mice were collected and centrifuged at 3000 rpm for 14 minutes at 4°C. The supernatant was transferred to a clean centrifuge tube. The plasma was mixed with an equal volume of protein A / G agarose beads, and then RIPA lysis buffer was added. The mixture was inverted and mixed at 4°C overnight. The mixture was centrifuged at 8000 rpm for 5 minutes at 4°C to remove the agarose beads. The supernatant was transferred to a new centrifuge tube and heated at 95°C for 10 minutes after BCA protein quantification.
[0087] After the samples were cooled, 100 μg of protein samples were taken and electrophoresed at 80 V for 30 minutes and 110 V for 50 minutes using 7.5% separation gel. The transfer conditions were: constant voltage 100 V for 120 minutes, followed by washing the membrane once with TBST buffer and blocking with 5% skim milk at room temperature for 1 hour.
[0088] Place the membrane in the primary antibody and incubate overnight at 4°C on a shaker. Wash three times with TBST buffer the next day for 5 minutes each time. Then add HRP-labeled secondary antibody and incubate at room temperature for 1 hour. Add an appropriate amount of chemiluminescent substrate to the membrane and detect protein bands using a chemiluminescent detector.
[0089] Results reference Fig.11 The expression level of ceruloplasmin in homozygous Atp7b gene knockout mice was significantly lower than that in wild-type mice.
[0090] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. An animal model of hepatolenticular degeneration, It is characterized in that The Atp7b gene in the animal model is not expressed or its expression is inhibited, so that the animal model exhibits characteristics of Wilson's disease.
2. A method for constructing an animal model of hepatolenticular degeneration, It is characterized in that By using non-homologous recombination repair to introduce mutations, the Atp7b gene protein in the animal model was subjected to frame shift and loss of function.
3. The method according to claim 2, It is characterized in that Guide RNA was designed for the intron 1 and intron 3 sequences of the Atp7b gene, and the Atp7b gene was knocked out by specifically removing the entire exon 2 region.
4. A method for constructing an animal model of hepatolenticular degeneration, It is characterized in that The method comprises the following steps: (1) Obtain Cas9 mRNA and two gRNAs by in vitro transcription; (2) Microinjection of Cas9 mRNA and gRNA into fertilized eggs of C57BL / 6J mice; (3) The injected fertilized eggs are transplanted into pseudo-pregnant female mice, and the mice born are F0 generation mice; (4) genotyping by PCR amplification and sequencing; (5) F0 mice that were positive for PCR amplification and sequencing were mated with C57BL / 6J mice to obtain positive F1 mice; (6) The F1 generation mice with stable inheritance continued to mate and reproduce to obtain homozygous mutant Atp7b-deficient mice.
5. An animal model of hepatolenticular degeneration, It is characterized in that The animal model is constructed by the construction method of claim 2 or 3 or 4.
6. A method of using the animal model described in claim 5 as a method for studying the pathogenesis of hepatolenticular degeneration or developing new drugs.
7. The use according to claim 6, It is characterized in that The animal model is used as a hepatolenticular degeneration disease model for the study of copper metabolism disorder diseases.
8. The use according to claim 6, It is characterized in that The animal model is used to clarify the disease mechanism of asymptomatic Wilson's disease, enrich the theoretical basis of Wilson's disease, and assist in the research and development of treatment methods for Wilson's disease.
